KUALA LUMPUR: CGS-CIMB Equities Research is retaining its Add call for Duopharma Biotech with an unchanged target price of RM3.67 due to the potential long-term earnings prospects from the development of vaccine manufacturing capabilities, which is a key rerating catalyst.
It said on Monday it was keeping its forecasts intact for now pending the details or further developments in the supply agreement for the Sinopharm vaccine, which it thinks could be signed by end of the month.
“We retain our Add call on the stock with an unchanged TP of RM3.67 based on a CY22F P/E of 28.8 times (+2 standard deviations from its five-year mean),” the research house said.
Significantly shorter review time for WHO-approved vaccines
malaysiakini.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from malaysiakini.com Daily Mail and Mail on Sunday newspapers.
Malaysian PM lays out four-step plan for post-Covid exit
phnompenhpost.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from phnompenhpost.com Daily Mail and Mail on Sunday newspapers.
Malaysia s daily vaccination rate surpassed 200,000 level for first time on June 15 — JKJAV
msn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from msn.com Daily Mail and Mail on Sunday newspapers.